Founding offer · lifetime membership for a single £24, exclusive to our first members · closes 20 June Claim your place →
Global Research Partnerships £24 Lifetime Log inCreate free account

Funded Projects › H2020

C-TCS · A Disruptive Treatment Control Software for Particle Therapy Centers

H2020Status: CLOSED1 August 201830 November 2018EU funding €50,000Call H2020-EIC-SMEInst-2018-2020

Cancer is one of the leading causes of death nowadays; 1 in every 2 men and 1 in every 3 women will be diagnosed with cancer at some point of their lives. The number of cancer incidences is growing by 2.4% annually, which puts a financial burden on healthcare systems globally. Particle therapy – PT (proton/neutron/positive ion therapy) has been proven to be effective and a safer alternative to other types of external beam radiotherapy as the charged particle dose is delivered in a narrow range and there is minimal damage to surrounding tissue. In 2015, among all patients that were treated for cancer worldwide, 25% were treated using some sort of radiation. However, building PT centres is very costly (>100M €) which has been a crucial factor in the slow adoption of PT facilities. This is likely to change due to introduction to lower cost/compact systems, and, more importantly, growing clinical evidence regarding its efficacy. A critical part of a PT centre is its treatment control system (TCS), the software that synchronizes the operation of all the devices. Currently, PT centre equipment vendors each custom develop their own TCS, which works only with their own equipment, is of limited configurability, closed to adjustments and expensive. Cosylab is a Slovenian company specializing in the field of control systems for particle accelerators with 17 years of experience in the field. We are developing our TCS (C-TCS) as an off-the-shelf product, that is universally usable on all vendors´ (integrators or manufacturers´) equipment. Our solution is easily configurable, available without lead times, and costing 3-5x-less than custom development. Overall, the C-TCS provides better cancer treatment efficacy, lower production and maintenance cost of PT facility, higher throughput of patients (resulting in more people treated). In 5 years after completion of the project (2025) we expect to employ additional 20 people and achieve a ROI of 5.6.

Consortium · 1 organisation

coordinator

COSYLAB LABORATORIJ ZA KONTROLNE SISTEME DD

SI · €50,000

Research fields

View the official record on CORDIS →

← Find collaborators and more funded projects

Source: CORDIS, Publications Office of the European Union. Global Research Partnerships surfaces open EU research data to help you find collaborators; we are not affiliated with the European Union.